Ryan McBride wrote:
Amag Pharmaceuticals (NASDAQ:AMAG), a Lexington, MA-based firm with a lead product for patients with chronic kidney disease, announced yesterday that it plans to sell 3 million shares of common stock in a public offering. Additionally, the firm is allocating 450,000 shares for underwriters to cover potential over-allotments. The company’s stock traded at $49.03 per share at 3:23 pm ET today.
